Short Interest in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Grows By 30.1%

by · The Cerbat Gem

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Get Free Report) was the target of a large growth in short interest in December. As of December 15th, there was short interest totaling 549,299 shares, a growth of 30.1% from the November 30th total of 422,094 shares. Based on an average daily volume of 97,160 shares, the days-to-cover ratio is presently 5.7 days. Currently, 1.5% of the shares of the stock are sold short. Currently, 1.5% of the shares of the stock are sold short. Based on an average daily volume of 97,160 shares, the days-to-cover ratio is presently 5.7 days.

Eupraxia Pharmaceuticals Trading Down 0.5%

EPRX stock traded down $0.04 during mid-day trading on Wednesday, hitting $7.55. 63,481 shares of the stock were exchanged, compared to its average volume of 142,325. The business has a fifty day moving average price of $6.27 and a 200 day moving average price of $5.71. Eupraxia Pharmaceuticals has a 12 month low of $2.68 and a 12 month high of $8.00.

Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.04. Equities analysts anticipate that Eupraxia Pharmaceuticals will post -0.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on EPRX. Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research note on Wednesday, October 8th. Wall Street Zen raised Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Finally, Leede Financial raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $11.67.

View Our Latest Stock Analysis on Eupraxia Pharmaceuticals

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. purchased a new position in Eupraxia Pharmaceuticals in the 3rd quarter worth $1,475,000. Vivo Capital LLC bought a new position in shares of Eupraxia Pharmaceuticals during the third quarter valued at about $7,965,000. Velan Capital Investment Management LP purchased a new position in shares of Eupraxia Pharmaceuticals in the third quarter worth about $2,077,000. Integrated Wealth Concepts LLC bought a new stake in shares of Eupraxia Pharmaceuticals in the 3rd quarter valued at about $71,000. Finally, Bank of America Corp DE boosted its holdings in Eupraxia Pharmaceuticals by 262.9% during the 3rd quarter. Bank of America Corp DE now owns 45,577 shares of the company’s stock valued at $269,000 after acquiring an additional 33,018 shares during the period.

Eupraxia Pharmaceuticals Company Profile

(Get Free Report)

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.

See Also